IRL 3461

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: IRL 3461
• 英文别名: N-butanesulfonyl-[N-(3,5-dimethylbenzoyl)-N-methyl-3-[4-(5-isoxazolyl)phenyl]-D-alanyl]-L-valineamide；IRL 3630；N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide；N-[(2R)-1-[[(2S)-1-(butylsulfonylamino)-3-methyl-1-oxobutan-2-yl]amino]-3-[4-(1,2-oxazol-5-yl)phenyl]-1-oxopropan-2-yl]-N,3,5-trimethylbenzamide
• 化学式: C₃₁H₄₀N₄O₆S
• 分子量: 596.748
• InChiKey: IFLIQLQVUMXNFU-IAPPQJPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  147
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3,5-二甲基苯甲酸 在 lithium hydroxide 、 sodium hydride 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 IRL 3461
  参考文献：
  名称：

  Discovery of IRL 3461: a novel and potent endothelin antagonist with balanced ETA/ETB affinity

  摘要：

  IRL 3461, N-butanesulfonyl- [N-(3,5-dimethylbenzoyl) -N-methyl-3-[4-(5-isoxazolyl)-phenyl]-alanyl]-(L)-valineamide, a potent and bifunctional (ETA+ETB) [Ki(ETA)= 1.8 nM, Ki(ETB)= 1.2 nM] antagonist was discovered by structural modification of IRL 2500, an ET, selective antagonist. IRL 3461 was found to be stable on incubation with human, rat, mouse, and guinea pig plasmas. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00387-4

文献信息

• Therapeutic treatments using centhaquin
  申请人：MIDWESTERN UNIVERSITY

  公开号：US10828368B2

  公开（公告）日：2020-11-10

  Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.

  公开了使用肾上腺素能制剂（如仙人掌）治疗高血压、疼痛和抢救失血性休克的方法。这些方法可治疗哺乳动物，包括人类。
• Stereoselective synthesis of a novel and bifunctional endothelin antagonist, IRL 3630
  作者：Junichi Sakaki、Toshiki Murata、Yoko Yuumoto、Ikushi Nakamura、Kenji Hayakawa

  DOI：10.1016/s0960-894x(98)00388-6

  日期：1998.8

  IRL 3630 (3), a single enantiomer of IRL 3461 with more potency was identified. Coupling reaction of the racemic fragment (1) with the chiral (L)-valinesulfonamide (2) under a biphasic solvent system (CH2Cl2-H2O) successfully led to the predominant formation of the desired isomer (3) with concomitant isomerization of 1. IRL 3630, N-butanesulfonyl-[N-(3,5-dimethylbenzoyl)-N-methyl-3-[4-(5-isoxazolyl)-phenyl]-(D)-alanyl]-(L)-valineamide, is a highly potent and bifunctional (ETA+ETB) antagonist [Ki(ETA)=1.5 nM, Ki(ETB)=1.2 nM]. (C) 1998 Elsevier Science Ltd. All rights reserved.
• METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS
  申请人：Midwestern University

  公开号：EP2424530B1

  公开（公告）日：2015-12-16
• Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic
  申请人：Gulati Anil

  公开号：US20080207763A1

  公开（公告）日：2008-08-28

  A composition and method of treating fever, and optionally treating pain, is disclosed. The composition and method utilize a nonopioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular disorders, like myocardial infarction.
• Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging
  申请人：Gulati Anil

  公开号：US20080260634A1

  公开（公告）日：2008-10-23

  Methods of imaging tumors are disclosed. The methods utilize an endothelin ET B receptor agonist or an endothelin ET A receptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans.